Your browser doesn't support javascript.
loading
The Chemokine CXCL14 as a Potential Immunotherapeutic Agent for Cancer Therapy.
Giacobbi, Nicholas S; Mullapudi, Shreya; Nabors, Harrison; Pyeon, Dohun.
Afiliación
  • Giacobbi NS; Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 48824, USA.
  • Mullapudi S; Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 48824, USA.
  • Nabors H; Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 48824, USA.
  • Pyeon D; Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 48824, USA.
Viruses ; 16(2)2024 02 16.
Article en En | MEDLINE | ID: mdl-38400076
ABSTRACT
There is great enthusiasm toward the development of novel immunotherapies for the treatment of cancer, and given their roles in immune system regulation, chemokines stand out as promising candidates for use in new cancer therapies. Many previous studies have shown how chemokine signaling pathways could be targeted to halt cancer progression. We and others have revealed that the chemokine CXCL14 promotes antitumor immune responses, suggesting that CXCL14 may be effective for cancer immunotherapy. However, it is still unknown what mechanism governs CXCL14-mediated antitumor activity, how to deliver CXCL14, what dose to apply, and what combinations with existing therapy may boost antitumor immune responses in cancer patients. Here, we provide updates on the role of CXCL14 in cancer progression and discuss the potential development and application of CXCL14 as an immunotherapeutic agent.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quimiocinas / Neoplasias Límite: Humans Idioma: En Revista: Viruses Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quimiocinas / Neoplasias Límite: Humans Idioma: En Revista: Viruses Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza